News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Karyopharm Therapeutics (KPTI) Announces Initiation Of An Investigator Sponsored Phase 1 Dose Escalation Study Of Its Lead Drug Candidate Selinexor (KPT-330) In Singapore



2/27/2014 9:16:07 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NATICK, Mass., Feb. 27, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced the initiation of a Phase 1 study of oral Selinexor in Asian patients with advanced or metastatic solid tumors. Selinexor (KPT-330), is a first-in-class, oral Selective Inhibitors of Nuclear Export (SINE) compound that covalently inhibits exportin-1 (XPO1/CRM1), which leads to the accumulation of tumor suppressor proteins in the cell nucleus and the selective induction of apoptosis in cancer cells. This study is designed to determine the recommended Phase 2 dose and assess the safety and preliminary evidence of anti-cancer activity in Asian patients.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES